Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737597 | 0.89 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL14417204 | 0.88 | ALDH1A1 (0.70) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL1162470 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL328468 | 0.82 | KDM4E (0.49) | ALDH1A1KDM4EHPGDLMNATP53 | |
| Hydrochloric Acid SCHEMBL251791 | 0.81 | KDM4E (0.48) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL14038322 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL13362573 | 0.78 | FEN1 (0.56) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL13814563 | 0.78 | KDM4E (0.45) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL195280 | 0.78 | P2RY12 (0.54) | ALDH1A1KDM4EHPGDLMNATP53 | |
| SCHEMBL1548586 | 0.77 | TP53 (0.62) | ALDH1A1KDM4EHPGDTP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8058284-B2 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090048216-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048216-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | ALDH1A1 1886/4885KDM4E 4459/4885HPGD 190/4885 |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | ALDH1A1 1886/4885KDM4E 4459/4885HPGD 190/4885 |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | P2RY4, P2RY6, P2RY13 | ALDH1A1 925/4885KDM4E 1862/4885HPGD 1160/4885 |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | P2RX7, P2RY1, P2RY6 | ALDH1A1 1579/4885KDM4E 3098/4885HPGD 2581/4885 |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | P2RX7, P2RY1, P2RY6 | ALDH1A1 1579/4885KDM4E 3098/4885HPGD 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.